We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...

Burnett-Bowie et al. investigated the efficacy and safety of the synthetic aromatase inhibitor anastrozole to treat hypogonadism in aging men. The study enrolled 88 men (60 years or older ...

The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

17 boys with constitutional delay of puberty randomly received either testosterone with placebo, or testosterone with the aromatase inhibitor letrozole, for 12 months. Patients were then followed ...

Metronomic capecitabine combined with an aromatase inhibitor extends median progression-free survival to 20.9 months compared with 11.9 months for aromatase inhibitor alone in hormone receptor ...